Abstract
Streptococcus pneumoniae is responsible for two-thirds of ICU admissions due to community-acquired pneumonia (CAP) and is the leading cause of CAP-related death. Early death is principally due to cardiovascular collapse, whereas late death is associated with hypoxemic respiratory failure. Outcome depends on interactions between non-modifiable factors of predisposition (age, comorbidities, host defences, genetic predisposition) or infection (toxins, virulence, bacterial burden) and modifiable factors (organ-failure support, surgical drainage for empyema, adjuvant therapies and antibiotics). Excess mortality has been reported when initial therapy is discordant, but more than 95% of isolates have minimum inhibitory concentration (MIC) < 4 μg/ml. Therefore, cefotaxime, ceftriaxone and high doses of amoxicillin remain successful for non-meningeal infections. Recent studies suggest that initial combination therapy improves survival in the subset of bacteremic episodes with highest severity, conceivably due to the immunomodulatory effects of macrolides. Prospective, randomized clinical trials of pneumonia patients with a pneumonia severity index score above 90 are warranted to define optimal antibiotic regimens.
Similar content being viewed by others
References
Garibaldi RA (1985) Epidemiology of community-acquired respiratory tract infections in adults: incidence, aetiology and impact. Am J Med 78:32S–38S
Guest JF, Morris A (1997) Community-acquired pneumonia: the annual cost to the National Health Service in UK. Eur Resper J 10:1530–1534
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250
Rello J, Bodi M, Mariscal D, Navarro M, Diaz E, Gallego M, Valles J (2003) Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 123:174–180. DOI 10.1378/chest.123.1.174
Bodí M, Rodríguez A, Solé-Violán J, Gilavert MC, Garnacho J, Blanquer J, Jimenez J, de la Torre MV, Sirvent JM, Almirall J, Doblas A, Badía JR, García F, Mendia A, Jordá R, Bobillo F, Vallés J, Broch MJ, Carrasco N, Herranz MA, Rello J. for CAPUCI study investigators (2005) Antibiotic prescription for community-acquired pneumonia in the intensive care unit. Impact of adherence to IDSA guidelines on outcome. Clin Infect Dis 41:1709–171 DOI 10.1086/498119
Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E, Rodriguez-Roisin R (1991) Severe community-acquired pneumonia. Epidemiology and prognostic factors Am Rev Respir Dis 144:312–318
Musher D, Alexandraki I, Graviss E, Yanbeiy N, Eid A, Inderias L, Phan H, Solomon E (2000) Bacteremic and non-bacteremic pneumococcal pneumonia: a prospective study. Medicine 79:210–221
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746
Waterer GW, Quasney MW, Cantor RM, Wunderink RG (2001) Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 163:1599–1604
Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278:2080–2084
Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF, PROWESS Clinical Evaluation Committee (2005) Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33:952–961. DOI 10.1097/01.CCM.0000162381.24074.D7
Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J (2004) Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med 32:625–631. DOI: 10.1097/01.CCM.0000114817.58194.BF
Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC, International Pneumococcal Study Group (2004) Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170:440–444. DOI 10.1164/rccm.200311–1578OC
Chow JW, Yu VL (1999) Combination antibiotic versus monotherapy for gram-negative bacteremia: a commentary. Int J Antimicrob Agents 11:7
American Thoracic Society (2001) Guidelines for the management of adults with community acquired pneumonia. Am J Respir Crit Care Med 163:1730–1754
Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31:347–382
British Thoracic Society (2001) BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56[Suppl 4]:1–64
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382. DOI 10.1136/thorax.58.5.377
Tighman RC, Finland M (1937) Clinical significance of bacteremia in pneumococcal pneumonia. Arch Intern Med 1937 59:602–619
Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, Miller GB, Witcomb MA, Isaacson M, Ward JI, Austrian R (1978) Emergency of multiply resistant pneumococci. N Engl J Med 299:735–740
Magnusdottir AB, Hermansson A, Melhus A (2000) Experimental study of the virulence of Streptococcus pneumoniae with reduced susceptibility to penicillin. Int J Pediatr Otorhinolaryngol 55:1–9
Rieux V, Carbon C, Azoulay-Dupuis E (2001) Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae. J Infect Dis 184:66–72
Azoulay-Dupuis E, Rieux V, Muffat-Joly M, Bedos JP, Vallee E, Rivier C, Isturiz R, Carbon C, Moine P (2000) Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob Agents Chemother 44:1575–1577
Aspa J, Rajas O, Rodriguez de Castro F, Blanquer J, Zalacain R, Fenoll A, de Celis R, Vargas A, Rodriguez Salvanes F, Espana PP, Rello J, Torres A; Pneumococcal Pneumonia in Spain Study Group (2004) Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 38:787–798
Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D (1997) Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 24:1052–1059
Winston LG, Perlman JL, Rose DA, Gerberding JL (1999) Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis 29:580–585
Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F (1995) Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 333:474–480
Ewig S, Ruiz M, Torres A, Marco F, Martinez JA, Sanchez M, Mensa J (1999) Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 159:1835–1842
Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J (2003) Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:389–385
Metlay JP, Hoffman J, Cetron MS (2000) Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 90:520–528
Musher DM, Bartlett JG, Doern GV (2001) A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics. Arch Intern Med 161:2538–2544
Crnich CJ, Proctor RA (2004) Treatment of pneumococcal pneumonia: what's in an MIC? Crit Care Med 32:876–878. DOI 10.1097/01.CCM.0000114999.81252.B5
Lipman J, Wallis SC, Rickard CM, Fraenkel D (2001) Low cefpirome levels during twice-daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 27:363–370
Craig WA (2004) Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am J Med 117 [Suppl 3A]:16S–22S
Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS (2004) Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from 5 years of the SENTRY Antimicrobial Surveillance Program. Clin Microbiol Infect 10:645–651
Yu, Campbell GD Jr, Siberman R (1998) Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 26:1188–1195
Reinert RR, Reinert S, van der Linden M, Cil MY, Al-Lahham A, Appelbaum P (2005) Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 49:2903–2913. DOI 10.1128/AAC.49.7.2903–2913.2005
Pihlajamaki M, Jalava J, Huovinen P, Kotilainen P, Finnish Study Group for Antimicrobial Resistance (2003) Antimicrobial resistance of invasive pneumococci in Finland in 1999–2000. Antimicrob Agents Chemother 47:1832–1835. DOI 10.1128/AAC.47.6.1832–1835.2003
Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 90:223–229
National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. Document M100–S12. National Committee for Clinical Laboratory Standards, Wayne, PA, USA
Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP, International Pneumococcal Study Group (2003) An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37:230–237
Song JH, Jung SI, Ki HK (2004) Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 38:1570–1578
National Committee for Clinical Laboratory Standards (1999) Performance standards for antimicrobial susceptibility testing. Ninth informational supplement. Document M100–S9. National Committee for Clinical Laboratory Standards, Wayne, PA, USA
Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM (2006) The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 42:788–797. DOI 10.1086/500140
Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen A, Gareen IF, Reiss PT, Medeiros AA (2002) Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35:556–564
Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J (2003) Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 51:691–696
Mortensen EM, Restrepo MI, Anzueto A, Pugh J (2006) The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 10:R8. DOI 10.1186/cc3934
Canton R, Morosini M, Enright MC, Morrissey I (2003) Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 52:944–952. DOI 10.1093/jac/dkg465
Davidson R, Cavalcanti R, Brunton JL (2002) Resistance to levofloxacin and failure of treatment of Pneumococcal Pneumonia. N Engl J Med 346:747–750
Rello J, Catalán M, Díaz E, Bodí M, Alvarez B (2002) Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 28:1030–1035. DOI 10.1007/s00134-002-1325–3
Mufson MA, Stanek RJ (1999) Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. Am J Med 107:34S–43S
Waterer G, Somes GW, Wunderink R (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842
Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D (2005) Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 24:688–690. DOI 10.1007/s10096-005-0018-6
Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, Izquierdo JL, Nikolaides P, Ogundare F, Raz R, Zuck P, Hoeffken G (2002) Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 46:1746–1754. DOI 10.1128/AAC.46.6.1746–1754.2002
Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, Reichl V, Freitag S, Bahal N, Wiesinger BA, Tennenberg A, Kahn JB (2002) A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 24:1292–1308
Sugiyama Y, Yanagisawa K, Tominaga SI, Kitamura S (1999) Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur Respir J 14:1113–1116
Khan AA, Slifer TR, Araujo FG, Remington JS (1999) Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 11:121–132
Lieberman D, Schlaeffer F, Boldur I et al (1996) Multiple pathogens in adult patients admitted with community-acquired pneumonia: a 1 year prospective study of 346 consecutive patients. Thorax 51:179–184
Almirall J, Bolibar I, Vidal J et al (2000) Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 15:757–763
Waterer RW, Rello J (2006) Choosing the right combination therapy in severe community-acquired pneumonia. Crit Care 10:115–116. DOI 10.1186/cc3976
Shorr AF, Bodi M, Rodriguez A, Sole-Violan J, Garnacho-Montero J, Rello J (2006) Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. ATS Conference, San Diego, May 2006
File TM jr, Tan JS, Boex JR (2006) The clinical relevance of penicillin-resistant Streptococcus pneumoniae: A new perspective. Clin Infect Dis 42:798–800. DOI 10.1086/500142
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by FISS PI 04/1500
Rights and permissions
About this article
Cite this article
Luján, M., Gallego, M. & Rello, J. Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Med 32, 971–980 (2006). https://doi.org/10.1007/s00134-006-0182-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-006-0182-x